Physical health in schizophrenia: a challenge for antipsychotic therapy

European Psychiatry : the Journal of the Association of European Psychiatrists
A Heald

Abstract

In the management of schizophrenia, mental health outcomes are the principal focus of treatment. The objective is to control the psychotic symptoms while minimising negative features of the illness, to achieve an overall improvement in the societal functioning of patients. Physical health is also important because if it is compromised, many of the benefits of improved mental health will be offset. Compared with the general population, schizophrenia patients are at increased risk of weight gain, abdominal obesity, diabetes, metabolic syndrome, and cardiovascular disease. These physical health problems can contribute to the decreased quality of life, lowered self-esteem and reduced life expectancy commonly reported in schizophrenia. For these reasons there is a pressing need to improve both the monitoring and the management of physical health in patients with schizophrenia as a part of their overall care. A consensus for metabolic monitoring of patients receiving treatment with antipsychotic drugs is available. However, the practicing clinician requires guidance about management of physical health in routine clinical practice. This should include recommendations for measurements that have strong predictive value about physical he...Continue Reading

References

Mar 31, 1998·The British Journal of Psychiatry : the Journal of Mental Science·S Brown
May 29, 1998·Circulation·P W WilsonW B Kannel
Feb 23, 1999·The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences·J M Flacker, L A Lipsitz
Apr 30, 1999·The Journal of Clinical Psychiatry·D B AllisonL J Cheskin
Mar 9, 2000·Schizophrenia Research·A HerránJ L Vázquez-Barquero
Sep 9, 2000·Schizophrenia Research·U OsbyP Sparén
May 23, 2001·JAMA : the Journal of the American Medical Association·UNKNOWN Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
Jul 24, 2001·Archives of Internal Medicine·A E FieldG A Colditz
Jan 5, 2002·The American Journal of Psychiatry·Peter TurroneAlastair J Flint
Jan 2, 2003·The British Journal of Psychiatry : the Journal of Mental Science·David M LawrenceMichael S T Hobbs
Jul 18, 2003·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Mythily SubramaniamElaine Pek
Jan 30, 2004·Diabetes Care·UNKNOWN American Diabetes AssociationUNKNOWN North American Association for the Study of Obesity
Jul 16, 2004·Primary Care Companion to the Journal of Clinical Psychiatry·Martha M. KatoMercedes Gonzalez-Blanco
Sep 27, 2005·Lancet·K George M M AlbertiUNKNOWN IDF Epidemiology Task Force Consensus Group
Nov 11, 2005·Journal of Psychopharmacology·Richard I G HoltLeslie Citrome
May 10, 2006·Diabetic Medicine : a Journal of the British Diabetic Association·H E MulnierR A Lawrenson
Jun 29, 2006·Clinical Practice and Epidemiology in Mental Health : CP & EMH·M De HertJ Peuskens
Dec 5, 2006·Schizophrenia Research·Guy FaulknerHyacinth Irving
Mar 9, 2007·European Psychiatry : the Journal of the Association of European Psychiatrists·Alp UçokSahap Erkoç
May 14, 2008·Archives of Internal Medicine·Dariush MozaffarianDavid S Siscovick
Jul 22, 2010·European Psychiatry : the Journal of the Association of European Psychiatrists·A-L Montejo

❮ Previous
Next ❯

Citations

Jul 22, 2010·European Psychiatry : the Journal of the Association of European Psychiatrists·C Höschl
Jul 22, 2010·European Psychiatry : the Journal of the Association of European Psychiatrists·A HealdC U Correll
Nov 28, 2013·Schizophrenia Research·Stephanie Deighton, Jean Addington
Oct 4, 2012·Schizophrenia Research·Yoichiro TakayanagiWilliam W Eaton
Jul 23, 2013·Schizophrenia Research·Vanessa NieratschkerIiris Hovatta
May 4, 2013·General Hospital Psychiatry·Denis G BirgenheirAmy M Kilbourne
Aug 2, 2012·Journal of Psychosomatic Research·En-Liang WuPesus Chou
Sep 27, 2013·International Journal of Psychiatry in Medicine·Francesco MargariVincenzo Palmieri
Jan 1, 2012·International Journal of Psychiatry in Medicine·J Lopez-CastromanE Baca-Garcia
Sep 17, 2016·The International Journal of Pharmacy Practice·Anna MygindLinda A Thomsen
Mar 30, 2017·The International Journal of Pharmacy Practice·Anna MygindLinda Aagaard Thomsen
Feb 5, 2011·Journal of Psychopharmacology·Thomas R E Barnes, UNKNOWN Schizophrenia Consensus Group of British Association for Psychopharmacology
Jun 27, 2013·Journal of Intellectual Disabilities : JOID·Sadira TeeluckdharryMeera Roy
Mar 7, 2018·Journal of Psychiatric Practice·Nuria Berrocal-IzquierdoMiguel Bernardo
May 1, 2015·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·Marie A LabouesseUrs Meyer
Jul 22, 2010·European Psychiatry : the Journal of the Association of European Psychiatrists·M De HertJ Peuskens
Jul 20, 2016·Journal of Clinical Psychopharmacology·Elena Rubio-AbadalUNKNOWN PROLACT Group
Jan 18, 2012·Current Opinion in Psychiatry·Thomas M LaursenMogens Vestergaard
May 18, 2020·European Archives of Psychiatry and Clinical Neuroscience·Christina J HeroldJohannes Schröder
Nov 28, 2020·Perspectives in Psychiatric Care·Maha KassemFrancois Kazour

❮ Previous
Next ❯

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.